Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253461 · ClinicalTrials.gov registry record · Early Phase 1
11C Topotecan PET Imaging
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT00253461 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT00253461, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I/II trial is studying how well a PET scan using 11C topotecan predicts response to treatment in patients with brain metastases due to ovarian, small cell lung, or other cancer.
Interventions
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- PROCEDURE computed tomography
- RADIATION 11C topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253461
The ClinicalTrials.gov registry entry for NCT00253461 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fludeoxyglucose F 18 is the first listed.
NCT00253461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00253461 about?
NCT00253461 is a clinical study titled "11C Topotecan PET Imaging". RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I/II trial is studying how well a PET scan using 11C topotecan predicts response to...
What is the current status of trial NCT00253461?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2004-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00253461?
The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), 11C topotecan (RADIATION).
Who is sponsoring clinical trial NCT00253461?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.